Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | APLNR | P35414 | 1/20 | 0.34 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.32 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27759741 | 0.86 | DPP4 (0.31) | DPP4APLNR | |
| SCHEMBL466188 | 0.80 | DPP4 (0.36) | DPP4APLNRSLC22A2SLC47A1 | |
| SCHEMBL25633183 | 0.78 | DPP4 (0.33) | DPP4APLNR | |
| SCHEMBL1838955 | 0.74 | DPP4 (0.34) | DPP4APLNR | |
| SCHEMBL3389689 | 0.73 | DPP4 (0.35) | DPP4 | |
| SCHEMBL17323775 | 0.72 | — | — | |
| SCHEMBL9647862 | 0.72 | RECQL (0.32) | SLC22A2SLC47A1MAPT | |
| SCHEMBL11249789 | 0.72 | APLNR (0.34) | APLNRSLC22A2SLC47A1MAPT | |
| SCHEMBL225385 | 0.72 | APLNR (0.34) | APLNRSLC22A2SLC47A1MAPT | |
| SCHEMBL10887105 | 0.72 | IDO1 (0.33) | APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1682109-A1 | THE USE OF 1-AMINOCYCLOHEXANE DERIVATIVES TO MODIFY DEPOSITION OF FIBRILLOGENIC AS PEPTIDES IN AMYLOIDOPATHIES | Merz Pharma GmbH & Co. KGaA (DE) | 2006-07-26 | — | — | EP | claimed |
| WO-2005079779-A1 | THE USE OF 1-AMINOCYCLOHEXANE DERIVATIVES TO MODIFY DEPOSITION OF FIBRILLOGENIC Aß PEPTIDES IN AMYLOIDOPATHIES | MERZ PHARMA GMBH & CO. KGAA (DE) | 2005-09-01 | — | — | WO | claimed |
| EP-2931277-A1 | METHODS AND COMPOSITIONS COMPRISING AKT INHIBITORS AND/OR PHOSPHOLIPASE D INHIBITORS | Vanderbilt University (US) | 2015-10-21 | — | — | EP | disclosed |
| WO-2014093557-A1 | METHODS AND COMPOSITIONS COMPRISING AKT INHIBITORS AND/OR PHOSPHOLIPASE D INHIBITORS | VANDERBILT UNIVERSITY (US) | 2014-06-19 | — | — | WO | disclosed |
| EP-2277850-A1 | 1-amino-alkylcyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists | Merz Pharma GmbH & Co. KGaA (DE) | 2011-01-26 | — | — | EP | disclosed |
| WO-2011001258-A1 | COMPOSITIONS, METHODS, AND KITS FOR TREATING VIRAL AND BACTERIAL INFECTIONS BY TOCOTRIENOLS, TOCOMONOENOLS, TOCODIENOLS, TOCOPHEROLS, AND THEIR DERIVATES | EVITA LIFE SCIENCE PTE. LTD (SG) | 2011-01-06 | — | — | WO | disclosed |
| US-20100076073-A1 | Combination of an NMDA receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders | MERZ PHARMA GMBH & CO. KGAA (DE) | 2010-03-25 | — | — | US | disclosed |
| EP-1765287-A2 | IMMEDIATE RELEASE FORMULATIONS OF MEMANTINE ORAL DOSAGE FORMS | Merz Pharma GmbH & Co. KGaA (DE) | 2007-03-28 | — | — | EP | disclosed |
| EP-1732530-A1 | 1-AMINOVYCLOHEXANE DERIVATIVES FOR THE TREATMENT OF AGITATION AND OTHER BEHAVIORAL DISORDERS, ESPECIALLY THOSE ASSOCIATED WITH ALZHEIMER'S DISEASE | Merz Pharma GmbH & Co.KGaA (DE) | 2006-12-20 | — | — | EP | disclosed |
| WO-2006096194-A2 | DRINKABLE IMMEDIATE RELEASE TABLET MADE WITH DIRECT COMPRESSION OF MEMANTINE OR NERAMEXANE | MERZ PHARMA GMBH & CO. KGAA (DE) | 2006-09-14 | — | — | WO | disclosed |
| EP-1684715-A2 | COMPOSITIONS COMPRISING CYCLOHEXYLAMINES AND AMINOADAMANTANES | Merz Pharma GmbH & Co. KGaA (DE) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005084655-A1 | 1-AMINOCYCLOHEXANE DERIVATIVES FOR THE TREATMENT OF AGITATION AND OTHER BEHAVIORAL DISORDERS, ESPECIALLY THOSE ASSOCIATED WITH ALZHEIMER’S DISEASE | MERZ PHARMA GMBH & CO. KGAA (DE) | 2005-09-15 | — | — | WO | disclosed |
| US-20050203191-A1 | 1-Aminocyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially those associated with alzheimer's disease | FOREST LABORATORIES, INC. (US) | 2005-09-15 | — | — | US | disclosed |
| EP-1556019-A2 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | Merz Pharma GmbH & Co. KGaA (DE) | 2005-07-27 | — | — | EP | disclosed |
| WO-2005044228-A2 | COMPOSITIONS COMPRISING CYCLOHEXYLAMINES AND AMINOADAMANTANES | MERZ PHARMA GMBH & CO. KGAA (DE) | 2005-05-19 | — | — | WO | disclosed |
| WO-2004037234-A2 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS | MERZ PHARMA GMBH & CO. KGAA (DE) | 2004-05-06 | — | — | WO | disclosed |
| EP-1228052-A1 | 1-CYCLIC AMINO-ALKYLCYCLOHEXANE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE AS ANTICONVULSANTS | Merz Pharmaceuticals GmbH (DE) | 2002-08-07 | — | — | EP | disclosed |
| WO-2001032640-A1 | 1-CYCLIC AMINO-ALKYLCYCLOHEXANE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR USE AS ANTICONVULSANTS | MERZ PHARMACEUTICALS GMBH (DE) | 2001-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203191-A1 | 1-Aminocyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially those associated with alzheimer's disease | ACHE, PNMT, APH1A | DPP4 2950/4885APLNR 981/4885SLC22A2 3305/4885 |
| US-20100076073-A1 | Combination of an NMDA receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders | GRIN2A, GRIN2B, GRIN3B | DPP4 2064/4885APLNR 316/4885SLC22A2 946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.